MEVOX

MEVOX is a private UK biotechnology company focused on next-generation protein vaccines for infectious diseases. The company applies molecular characterization, structure-based design, and protein engineering to create conformationally precise vaccine antigens intended to improve neutralizing antibody responses, durability, and manufacturability. Public materials indicate a particular focus on upgrading established vaccines and on measles and mumps vaccine programs, supported by an NIH-related license process. MEVOX positions itself as a platform-enabled vaccinology company that partners with external experts in antigen design, translational science, clinical development, regulation, and commercialization. The company appears to remain private and active, with an early-stage pipeline centered on prophylactic infectious disease vaccines.